Curatis

Curatis is a Swiss specialty pharmaceutical company specializing in the acquisition, development, and commercialization of innovative medicines for orphan and ultra-orphan diseases as well as specialty care indications. The company operates a dual business model: a profitable distribution business for third-party specialty medicines in Switzerland and a proprietary drug development pipeline focused on high unmet medical needs in CNS and oncology. Following its reverse merger with Kinarus Therapeutics in April 2024, Curatis has expanded its R&D portfolio to include the KIN001 platform while maintaining a robust commercial footprint with over 40 distributed products. The company's development strategy focuses on identifying compounds with existing safety and clinical efficacy data to accelerate the path to market with reduced investment risk, notably advancing its lead candidate C-PTBE-01 toward a pivotal Phase 3 trial.